Durata reveals upbeat data on antibiotic; OvaScience targets Nasdaq listing in Q1;

Conversation on Twitter :

 @FierceBiotech: Slideshow: FDA Approvals of 2012. More | Follow @FierceBiotech

@RyanMFierce: $BIIB has filed for FDA approval of long-lasting clotting factor in hemophilia B, a new area for the biotech giant. More | Follow @RyanMFierce

> Durata Therapeutics ($DRTX) revealed positive data on late-stage study for its antibiotic dalbavancin against skin infections. Item

> Venture-backed Proteon Therapeutics prevailed in a mid-stage study for its candidate used to prolong patency for patients on hemodialysis. Release

> Excela Pharma Sciences got kudos for its plans to add 38 jobs and invest $8.5 million at its facility in North Carolina. News

> OvaScience, which is developing female reproductive therapies, plans to make the jump from trading over-the-counter to the Nasdaq this fiscal quarter. Article

> Actinium Pharmaceuticals, a developer of immunotherapeutics, went public in a reverse merger and will be trading on the OTCBB under the symbol "CTVN." Announcement

Pharma News

@FiercePharma: Here's evidence of Vivus growth expectations: New HQ space almost 3X the size of current offices. More | Follow @FiercePharma

 @EricPFierce: The FDA approved nearly a dozen new cancer drugs in 2012, but also drugs for erectile dysfunction weight-loss. Special Report | Follow @EricPFierce

 @AlisonBFierce: Eli Lilly will step up to the plate to defend against DES litigation. News | Follow @AlisonBFierce

> Analyst says Vivus buyout, partner best for Qsymia sales. Report

> Lilly betting B12 can protect blockbuster Alimta from generics. Article

> Abbott said to be looking at buying Bausch & Lomb. Story

Medical Device News

 @FierceMedDev: Halt Medical snags $15M to launch uterine fibroid device. Story | Follow @FierceMedDev

@MarkHFierce: We at Fierce are gearing up for some major coverage of JPM13. The fun starts Monday in San Francisco. Editor's Corner | Follow @MarkHFierce

 @DamianFierce: Hologic is selling off one of the business units it acquired in last year's $3.8B Gen-Probe buy. News | Follow @DamianFierce

> GI Dynamics teams up with Medtronic, GSK for EndoBarrier research. News

> The U.K.'s Wellcome Trust unveils VC fund for devices, Dx and others. Article

> Atossa revs up national sales rollout for handheld breast cancer Dx. Story

And Finally… Rhythm, a Boston biotech outfit with some big-name backers, says it began a Phase II study for RM-493 to treat obesity. Release

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.